No Picture
News

Helix Selected by the NIH to Become One of the Nation’s COVID-19 “Mega-Labs” and Scale Daily Capacity to 100,000 Tests

Funding from the NIH RADx-ATP program will be used to support rapid scaling of Helix’s end-to-end COVID-19 test system, making it one of the highest throughput COVID-19 laboratories in the country

SAN MATEO, Calif., July 31, 2020 /PRNewswire/ — Heli… […]

No Picture
News

Roche snags an FDA approval for an advanced melanoma drug cocktail — but it’s up against some fierce competition

Roche’s PD-L1 inhibitor Tecentriq snagged an FDA approval to treat certain advanced melanoma patients in a three-drug cocktail, providing another option for patients with a typically poor prognosis.
In a Phase III IMspire150 study, Tecentriq combined w… […]

No Picture
News

Tetraphase deal done, La Jolla Pharmaceutical taps Larry Edwards as CEO; Longtime Eli Lilly exec Michael Overdorf heads to Annexon as CBO

Larry Edwards
→ As La Jolla Pharmaceutical closed on their acquisition of Tetraphase on Wednesday, the San Diego biotech also announced that they’re taking the president and CEO right along with them as Larry Edwards steps in. Edwards, who had a 15-yea… […]

No Picture
News

Covid-19 roundup: Despite Q2 sales setback, Gilead revises 2020 sales projection upward thanks to remdesivir

The Covid-19 pandemic hit Gilead hard in the second quarter, but the pharma company expects that to change for the better thanks to remdesivir.
Johanna Mercier
After announcing a 10 percent drop in sales in a quarterly earnings call with investors Thur… […]

No Picture
News

Sangamo and Novartis join forces to create gene therapies for autism and other brain disorders

Bay Area biotechnology company Sangamo Therapeutics has teamed up with multinational pharmaceutical giant Novartis International AG to take on autism spectrum disorder and other neurodevelopmental conditions.

The collaboration, announced Thursday, wil… […]

No Picture
News

Gilead Sciences Announces Second Quarter and First Half 2020 Financial Results

FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter and first half 2020. “Gilead’s first half performance demonstrates the strength and durability of our core HIV b… […]